Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

By Tarun Sai Lomte While GLP-1 receptor agonists like semaglutide help with weight loss, new research shows users often fall ...

News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...

Patients taking a GLP-1 for diabetes have a lower risk for AF at 3 years than those on other medications, report ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

FuturHealth offers both compounded semaglutide and FDA-approved name-brand options like Wegovy and Ozempic. For most users, ...

In clinical trials, semaglutide proved to be superior to placebo, with weight loss reaching 15%, suggesting its superiority over other non-GLP-1 RA anti-obesity medications. Participants ...

“Our study found a similar incidence of obesity-related cancer among patients treated with first-generation glucagon-like peptide-1 receptor ... effect of GLP-1RAs beyond weight-loss to be ...